menu
    • menu
    [{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"GPH101","moa":"Hemoglobin beta chain","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"GPH101","moa":"Hemoglobin beta chain","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"GPH101","moa":"Hemoglobin beta chain","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"GPH102","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Graphite Bio","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Graphite Bio"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Kamau Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nulabeglogene Autogedtemcel","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Kamau Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Kamau Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Graphite Bio

    Menu

    Graphite Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Versant Ventures

                            Deal Size : $53.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            LENZ Completes Merger with Graphite Bio and Updates On Progress

                            Details : The net proceeds will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free, single-use, once-daily eye drops for treating presbyopia.

                            Brand Name : LNZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 21, 2024

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Versant Ventures

                            Deal Size : $53.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            LENZ Completes Merger with Graphite Bio and Provides Clinical and Corporate Update

                            Details : The collaboration will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free eye drops containing aceclidine and aceclidine plus brimonidine for presbyopia treatment.

                            Brand Name : LNZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 21, 2024

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nulabeglogene Autogedtemcel

                            Therapeutic Area : Hematology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Kamau Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Th...

                            Details : Under the agreement, Kamau will focus on the clinical development of lead program Nula-Cel (nulabeglogene autogedtemcel), which is being evaluated in Phase I/II clinical trial studies for the treatment of sickle cell disease.

                            Brand Name : Nula-Cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Nulabeglogene Autogedtemcel

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Kamau Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : LENZ Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            LENZ Therapeutics and Graphite Bio Announce Merger Agreement

                            Details : The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.

                            Brand Name : LNZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : LENZ Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Versant Ventures

                            Deal Size : $53.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            LENZ Therapeutics and Graphite Bio Announce Merger Agreement

                            Details : The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyo...

                            Brand Name : LNZ101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2023

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Versant Ventures

                            Deal Size : $53.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nulabeglogene Autogedtemcel

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of Nulabeglogene Autogedtemcel (nula-Cel) for ...

                            Details : GPH101 (nula-cel), is an investigational next-generation gene editing autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).

                            Brand Name : GPH101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 06, 2023

                            Lead Product(s) : Nulabeglogene Autogedtemcel

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nulabeglogene Autogedtemcel

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

                            Details : Nula-cel, formerly known as GPH101, is an investigational next-generation gene-editing autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).

                            Brand Name : GPH101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 11, 2022

                            Lead Product(s) : Nulabeglogene Autogedtemcel

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GPH102

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annu...

                            Details : GPH102 is designed to replace the mutated beta-globin gene with a functional gene and restore adult hemoglobin (HbA) expression to levels similar to individuals who do not have the disease.

                            Brand Name : GPH102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 16, 2022

                            Lead Product(s) : GPH102

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GPH101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

                            Details : First patient expected to be treated by GPH101 in first half of 2022, GPH101 an investigational next-generation gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.

                            Brand Name : GPH101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 17, 2021

                            Lead Product(s) : GPH101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Graphite Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GPH101

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Dis...

                            Details : The preclinical data support CEDAR clinical trial, a Phase 1/2 study evaluating the safety, pharmacodynamics, engraftment success, gene correction rates and total hemoglobin, as well as other clinical and exploratory endpoints of GPH101 in patients with ...

                            Brand Name : GPH101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 12, 2021

                            Lead Product(s) : GPH101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth